Swiss pharmaceutical giant Novartis has recently been on the receiving end of two significant enforcement actions: the first for violations of the Foreign Corrupt Practices Act; the second for violations of the False Claims Act and Anti-Kickback Statute.
Tom Fox details the bribery schemes and the internal control failures, outlines just how much Novartis has lost as a result and offers key takeaways for compliance practitioners.
Download the whitepaper below.
Foster Wheeler has recently settled a long-standing corruption investigation regarding the use of Unaoil to pay bribes to secure business....
Per the DOJ and SEC, “successor liability applies to all kinds of criminal and civil liabilities, and FCPA violations are...
Good ethics is good business. Yonason Goldson, Director of Ethical Imperatives, LLC and self-proclaimed ethics ninja, works with leaders to...
TrustArc, the leader in data privacy management and automation has released its 2021 TrustArc Global Privacy Benchmarks Report. Now in...
